Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
It has been reported that low-dose aspirin and Heparin would lead to an increased Pregnancy rate in patients undergoing IVF-ET. Low-dose aspirin may improve uterine and ovarian perfusion and that aspirin might enhance endometrial receptivity and ovarian responsiveness as well, which could result in better implantation and pregnancy rates after IVF or ICSI treatment. This study assesses potential effects of low-dose aspirin (100 mg daily) on pregnancy rate following frozen embryo transfer.
In the present randomized double-blind prospective study, the patients will be randomly assigned to the study and control groups. With the onset of endometrial preparation and estrogen treatment, the study group will receive 100 mg of oral aspirin and the control group will be given placebo. When endometrial thickness will be found between 8-14 mm, therapy with progesterone (100 mg IM daily) will be started and embryo transfer will be performed 48 to 72 hours later. Doppler ultrasonography also is done to calculate Resistive Index (RI) and Pulsatility Index (PI), the day after progesterone administration.
βHCG will be assessed 14 days after ET. If a pregnancy will be achieved, the patients in study and control groups will be instructed to continue the aspirin or placebo through 5 weeks and if the pregnancy test result will be negative, the treatment with aspirin or placebo will be stopped. The patients will be followed until 20 weeks of gestation and the results of treatment cycle will be compared in two groups.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Asprin | Experimental | With the onset of endometrial preparation and estrogen treatment, the study group will receive 100 mg of oral aspirin. |
|
| placebo | Placebo Comparator | With the onset of endometrial preparation and estrogen treatment, the control group will receive placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Asprin | Drug | 100 mg |
| |
| placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Pregnancy rate | evaluation the clinical pregnancy rate 6 weeks after emberyo transfering. | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Implantation rate | Evaluation the implantation rate after emberyo transfer in women who use low dose of aspirin | 8 weeks |
| Miscarriage rate | Evaluation the miscariage rate after emberyo transfer in women who use asprin. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hamid Gourabi, PhD | Head of Royan institute | Study Chair |
| Tahereh Madani, MD | Endocrinology and Female Infertility Department | Study Director |
| Firoozeh Ahmadi, MD | Reproductive Imaging Department | Principal Investigator |
| Poopak Eftekhary, PhD | Embryology Department | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royan Institute | Tehran | Iran |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D007246 | Infertility |
| ID | Term |
|---|---|
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C010395 | acetylsalicylic acid lysinate |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
100mg |
|
| 12 weeks |